Migraine in Adults: Preventive Pharmacologic Treatments

Published: 15 November 2018| Version 1 | DOI: 10.17632/5ng63z84vk.1
Contributor:
Tatyana Shamliyan

Description

Suggested citation: Shamliyan TA, Kane RL, Taylor FR. Migraine in Adults: Preventive Pharmacologic Treatments. Comparative Effectiveness Review No. 103. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. 290-2007-10064-I) AHRQ Publication No. 13-EHC068-EF. Rockville, MD: Agency for Healthcare Research and Quality; April 2013. www.effectivehealthcare.ahrq.gov/reports/final.cfm. This report is based on research conducted by the Minnesota Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10064-I).

Files

Steps to reproduce

We abstracted the information relevant to the PICOTS framework. We abstracted minimum datasets to reproduce the results presented by the authors. For categorical variables, we abstracted the number of events among treatment groups to calculate rates, relative risk, and absolute risk differences. We abstracted means and standard deviations of continuous variables to calculate mean differences with a 95% confidence interval (CI). We abstracted the number randomized to each treatment group as the denominator to calculate estimates by applying intention-to-treat principles assuming that the same proportions apply in the missing data. We abstracted drug regimen and doses and patient characteristics including demographics, baseline frequency and severity, and prior treatment status as factors that can modify treatment effects. We abstracted sponsorship of the studies and conflict of interest by the authors. We incorporated risk of bias in individual studies into the synthesis of evidence by using individual risk of bias criteria rather than a global score or a ranking category of overall risk of bias.